Testing a medication to prevent heart rhythm problems after certain strokes

This trial is testing whether empagliflozin, a medication originally developed for diabetes, can prevent irregular heart rhythms (called atrial fibrillation) in people who've had a stroke with no clear cause. About half of people in this situation develop irregular heartbeats within a few years, which increases their risk of another stroke. The study will compare people taking this medication alongside standard stroke care against people receiving standard care alone.

Many people who have a stroke with an unclear cause later develop dangerous irregular heartbeats, putting them at risk for another stroke. Current treatments require blood thinners, which carry serious bleeding risks. This trial is exploring whether this medication might prevent irregular heartbeats from developing in the first place—potentially offering a safer alternative.